Core Insights - Alvotech and Advanz Pharma have expanded their commercial partnership to include three additional biosimilar candidates, enhancing their collaboration in the European market [1][2][8] Group 1: Partnership Details - The new agreement includes biosimilar candidates to Ilaris® (canakinumab) and Kesimpta® (ofatumumab), along with a third undisclosed candidate, with Alvotech responsible for development and supply, while Advanz Pharma handles registration and commercialization in Europe [2][4] - The agreement encompasses development and commercial milestones totaling up to US$180 million (EUR 160 million) and includes a revenue-sharing model between the partners [2][4] Group 2: Market Potential - The partnership now covers proposed biosimilars referencing over ten originator biologics, with the current addressable market for these products in the relevant countries estimated at least US$13.8 billion [5][3] - Advanz Pharma aims to broaden access to rare disease and specialty medicines through this expanded collaboration, reinforcing its growth strategy in the biosimilars sector [4][3] Group 3: Company Background - Alvotech is focused on developing and manufacturing biosimilar medicines, with a pipeline that includes eight disclosed candidates targeting various diseases, including autoimmune disorders and cancer [7] - Advanz Pharma operates globally, with a focus on specialty, hospital, and rare disease medicines, and has a commercial presence in over 90 countries [10]